ID   HT29-19A
AC   CVCL_0323
SY   HT2919A; HT 29/19A; HT29/19A; HT29 cl.19A; HT29-cl19A; HT29 CL19A; HT29 cl 19A; HT 29 cl.19A; HT29-Cl.19A; HT-29 clone 19A; HT29 clone 19A; HT29clone19A
DR   MCCL; MCC:0000216
DR   cancercelllines; CVCL_0323
DR   Wikidata; Q54896591
RX   PubMed=6744312;
RX   PubMed=12508250;
RX   PubMed=12714179;
RX   PubMed=15463957;
RX   PubMed=25944804;
CC   Population: Caucasian.
CC   Doubling time: 43.47 hours (PubMed=25944804).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0320 ! HT-29
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=6744312;
RA   Augeron C., Laboisse C.L.;
RT   "Emergence of permanently differentiated cell clones in a human
RT   colonic cancer cell line in culture after treatment with sodium
RT   butyrate.";
RL   Cancer Res. 44:3961-3969(1984).
//
RX   PubMed=12508250; DOI=10.1002/gcc.10163;
RA   Kuechler A., Weise A., Michel S., Schaeferhenrich A., Pool-Zobel B.L.,
RA   Claussen U., Liehr T.;
RT   "Precise breakpoint characterization of the colon adenocarcinoma cell
RT   line HT-29 clone 19A by means of 24-color fluorescence in situ
RT   hybridization and multicolor banding.";
RL   Genes Chromosomes Cancer 36:207-210(2003).
//
RX   PubMed=12714179; DOI=10.1016/S0027-5107(03)00012-5;
RA   Schaeferhenrich A., Beyer-Sehlmeyer G., Festag G., Kuechler A.,
RA   Haag N., Weise A., Liehr T., Claussen U., Marian B., Sendt W.,
RA   Scheele J., Pool-Zobel B.L.;
RT   "Human adenoma cells are highly susceptible to the genotoxic action of
RT   4-hydroxy-2-nonenal.";
RL   Mutat. Res. 526:19-32(2003).
//
RX   PubMed=15463957; DOI=10.1016/j.jcf.2004.05.040;
RA   Gruenert D.C., Willems M., Cassiman J.-J., Frizzell R.A.;
RT   "Established cell lines used in cystic fibrosis research.";
RL   J. Cyst. Fibros. 3:191-196(2004).
//
RX   PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457;
RA   Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E.,
RA   Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R.,
RA   Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.;
RT   "Highly expressed genes in rapidly proliferating tumor cells as new
RT   targets for colorectal cancer treatment.";
RL   Clin. Cancer Res. 21:3695-3704(2015).
//